Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021

Rhea-AI Summary

Jounce Therapeutics (NASDAQ: JNCE) has announced a virtual R&D Day scheduled for June 23, 2021, from 10:00 a.m. to 12:00 p.m. ET. The event will include presentations from Jounce management and scientific team members, featuring key opinion leader Robert Schreiber, PhD. Attendees can access the webcast through the Investors and Media section of Jounce's website. The company focuses on developing novel cancer immunotherapies and currently has multiple programs, including the promising JTX-8064 and vopratelimab, aimed at enhancing the immune response against tumors.

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it will host a virtual R&D Day at 10:00 a.m. – 12:00 p.m. ET on Wednesday, June 23, 2021.

The event will feature presentations and a Q&A session from Jounce management and scientific team members, in addition to key opinion leader and a Jounce scientific founder, Robert Schreiber, PhD, The Washington University School of Medicine.

A webcast of the R&D Day will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be available for 30 days following the presentation.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com

Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com

FAQ

What is the date and time for Jounce Therapeutics' R&D Day?

Jounce Therapeutics' virtual R&D Day is scheduled for June 23, 2021, from 10:00 a.m. to 12:00 p.m. ET.

Who will present at the JNCE R&D Day?

Presentations at the JNCE R&D Day will be made by Jounce management and scientific team members, including Robert Schreiber, PhD.

Where can I watch the Jounce Therapeutics R&D Day webcast?

The webcast for the Jounce Therapeutics R&D Day can be accessed on their website under the 'Events and Presentations' section.

What are Jounce Therapeutics' main programs?

Jounce Therapeutics is focused on developing immunotherapies, with key programs including JTX-8064 and vopratelimab.

What is the significance of JTX-8064 in JNCE's pipeline?

JTX-8064 is a receptor antagonist aimed at reprogramming immune-suppressive tumor-associated macrophages to enhance the anti-tumor response.